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MaCancer therapy can be associated with both cardiac and vascular toxicity. Advanced multi-modality imaging can be used
to stratify patient risk, identify cardiovascular injury during and after therapy, and forecast recovery. Echocardiography
continues to be the mainstay in the evaluation of cardiac toxicity. Particularly, echocardiography-based strain imaging is
useful for risk stratification of patients at baseline, and detection of subclinical left ventricle (LV) dysfunction during
therapy. Cardiac magnetic resonance (CMR) serves a complementary role in the patient with poor echocardiographic or
equilibrium radionuclide angiographic image quality or in situations where a more accurate and precise LV ejection
fraction measurement is needed to inform decisions regarding discontinuation of chemotherapy. New CMR techniques
like T1 and T2 mapping and positron emission tomography (PET) imaging will help us better understand the structural,
pathological, and metabolic myocardial changes associated with ventricular dysfunction or release of serum biomarkers.
CMR may also be helpful in the evaluation of vascular complications of cancer therapy. Stress echocardiography, stress
CMR, computed tomography, and PET are excellent imaging options in the evaluation of ischemia in patients receiving
therapies that could potentially cause vasospasm or accelerated atherosclerosis. (J Am Coll Cardiol Img 2018;11:1173–86)
© 2018 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.T he field of oncology has advanced remark-ably. In some instances, cancer is eithercured or converted to a chronic disease.
Nevertheless, some of the old and new emerging can-
cer therapies are associated with development of car-
diovascular toxicities (1,2), which may have the
potential to offset the gains in survival obtained
with these cancer treatment advances (3). Much of
the focus on cardiovascular toxicities has been in
the early detection of myocardial damage and predic-
tion of cancer therapeutics-related cardiac dysfunc-
tion (CTRCD). However, because the toxicities
associated with cancer therapies are much broaderN 1936-878X/$36.00
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modality imaging and how it can be used to stratify
patients’ risk before cancer therapy is started, iden-
tify early cardiovascular injury during therapy, pre-
dict recovery from injury, and detect cardiovascular
injury in long-term cancer survivors (Central
Illustration).
CLINICAL CASE
A 51-year-old female with left-sided, high-risk, early
stage human epidermal growth factor receptor
2-positive (HER2þ) breast cancer was referred to thehttps://doi.org/10.1016/j.jcmg.2018.06.003
ton, Texas; bTed Rogers Program in Cardiotoxicity
ty Health Network, University of Toronto, Toronto,
rch (NIHR) Biomedical Research Centre, University
he dDepartments of Cardiology and Cardiovascular
nterdisciplinaire de Génoprotéomique Appliquée
iège, Belgium, and Gruppo Villa Maria Care and
NIHR Biomedical Research Centre at University
iews expressed in this publication are those of the
Health Research or the Department of Health and
of Health Research New Investigator Award FRN
of Health Research Biomedical Research Centre.
ll other authors have reported that they have no
6, 2018, accepted June 18, 2018.
ABBR EV I A T I ON S
AND ACRONYMS
CAD = coronary artery disease
CMR = cardiac magnetic
resonance
CTRCD = cancer therapeutics-
related cardiac dysfunction
EDV = end-diastolic volume
ERNA = equilibrium
radionuclide angiocardiography
ESV = end-systolic volume
GLS = global longitudinal
strain
GCS = global circumferential
strain
HER2þ = human epidermal
growth factor receptor
2-positive
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1174cardio-oncology clinic. Her treatment plan
includedmastectomy, epirubicin, 300mg/m2,
17 cycles of trastuzumab, radiation therapy
(50 Gy), and hormone therapy. She had no
known cardiovascular risk factors, was not
receiving medications, and had excellent
functional capacity. Imaging and biomarker
assessments were performed prior to cancer
therapy, throughout her treatment, and 1
year later (Table 2). Her baseline blood pres-
sure was 138/80 mm Hg, cardiac examination
was unremarkable; her left ventricular ejec-
tion fraction (LVEF) by 3-dimensional (3D)
echocardiography was 61%; global longitu-
dinal strain (GLS) was 21.3%; and global
circumferential strain (GCS) was 20.3%.
Several questions were raised during her
initial consultation and follow-up: How doescardiac imaging play a role in identifying cardiovas-
cular toxicity risk in this patient? What is the best
method to detect early cardiac injury from treatment?
What are the predictors of ventricular function
recovery after cardiotoxicity?
ASSESSMENT OF BASELINE RISK OF
CARDIOVASCULAR COMPLICATIONS IN
PATIENTS RECEIVING CANCER THERAPY
ASSESSING RISK OF CTRCD AND HEART
FAILURE. American Society of Clinical Oncology
guidelines recommend risk stratification for cardiac
dysfunction prior to initiation of potentially car-
diotoxic cancer treatment. We refer the readers to
their discussion of which patients with cancer are at
increased risk of developing cardiac dysfunction (5).
From an imaging standpoint, patients with border-
line cardiac function (LVEF of 50% to 55%, a history
of myocardial infarction, and presence of other
cardiac comorbidities, e.g., $moderate valvular
heart disease) before the start of anthracycline or
trastuzumab therapy are at a 3.6- to 11.8-fold
increased risk for developing cardiac dysfunction
(5). The expert consensus for multi-modality imag-
ing evaluation of the adult patient during and after
cancer therapy recommends a baseline echocardio-
gram, with the calculation of LVEF, ideally using 3D
echocardiography and GLS if the technology is
available and the operators are comfortable with
their performance and interpretation (6). The latter
is a reflection of the superior reproducibility of 3D
LVEF and GLS measurements (7,8). In addition to
LVEF, pre-treatment measurements of GLS appear
to identify patients at elevated risk of major
adverse cardiac events in the context ofanthracycline therapy (9,10). Similarly, every 1%
difference in baseline circumferential strain has
been associated with 31% increased odds of car-
diotoxicity in women receiving breast cancer ther-
apy (11).
Cardiac magnetic resonance (CMR) is usually not
used as a first-line tool for risk stratification because
of its cost and lack of wide availability. However, in
patients with a nondiagnostic echocardiogram, un-
explained dilation of the left or right ventricles, or
morphological abnormalities raising concern for
infiltrative cardiomyopathy, CMR can complement
the echocardiographic evaluation to assess for a po-
tential cause. To date, however, there are no data to
determine whether pre-treatment CMR parameters
identify patients at risk for cardiotoxicity.
CORONARY ARTERY DISEASE RISK. Stress echocar-
diography may be useful in the evaluation of patients
with intermediate or high probability of coronary
artery disease (CAD) who are undergoing regimens
that may be associated with ischemia (e.g., 5-fluoracil,
capecitabine, bevacizumab, sorafenib, and sunitinib)
(6). Cardiac computed tomography (CCT) has changed
the landscape of coronary assessment in the field of
cardiology. Its role in cardio-oncology is primarily
restricted to assessment of coronary calcium and
obstructive CAD (12). Both nuclear and positron
emission tomography stress testing represent alter-
natives for the evaluation of CAD in these patients.
Stress CMR can detect the presence and extent of
inducible myocardial ischemia with high diagnostic
accuracy (13). The attraction of stress echocardiogra-
phy and stress CMR is the lack of radiation exposure.
However, stress echocardiography may be chal-
lenging in patients who have had mastectomies,
breast expanders, or implants. In those situations, the
use of ultrasonic enhancing agents may improve
visualization of the myocardial segments and accu-
racy of interpretation (14). CMR may not be feasible in
the presence of certain breast tissue expanders
because of their ferromagnetic components (6).
VASCULAR TOXICITY. Many agents used in cancer
treatment such as tyrosine kinase inhibitors,
vascular endothelial growth factor inhibitors, anti-
metabolites, and radiation therapy are associated
with direct vascular toxicity, whereas hormone
therapy can increase the risk of atherosclerotic
vascular events (15,16). Potential vascular toxicities
include hypertension, CAD, peripheral arterial dis-
ease, pulmonary hypertension, and venous throm-
bosis (16). Although certain clinical risk factors
for these toxicities have been described (e.g.,
pre-existing hypertension), unlike cardiomyopathy,
TABLE 1 Cardiovascular Toxicities Where Imaging Plays a Role in Risk Stratification,
Detection, or Prognosis















































2D ¼ 2-dimensional; CCT ¼ cardiac computed tomography; CMR ¼ cardiac magnetic resonance; CT ¼ computed
tomography; CTRCD ¼ chemotherapy-related cardiac dysfunction; Echo ¼ echocardiography; GLS ¼ global
longitudinal strain; PET ¼ positron emission tomography.
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1175there have been no reports that have examined
vascular imaging parameters to identify patients at
risk (16). The area of vascular risk in cancer survi-
vors, however, has gained significant attention with
the description of clonal hematopoiesis (CH) as a risk
factor for atherosclerotic vascular disease (17). CH is
an expansion of myeloid and lymphoid cells that
carry recurrent somatic mutations. CH appears to be
identified in approximately 10% of patients 70 to 79
years of age (18), with a 4-fold increased incidence
in patients receiving cancer therapy when compared
with untreated patients (19). Patients with CH are at
a 2.0- to 2.6-fold higher risk of coronary or cere-
brovascular disease (20). Therefore, identifying pa-
tients with CH and performing targeted vascular
imaging may be a novel future approach to risk
stratification.
EARLY IDENTIFICATION OF CARDIOVASCULAR
INJURY DURING CANCER THERAPY. Early detection of
CTRCD. Evaluation of LV volume and function.
Historically, planar equilibrium radionuclide angio-
cardiography (ERNA) and single-photon emission
computed tomography (SPECT)-ERNA provided
reliable and accurate means of calculation of LVEF.
However, although extensive research exists in
the cancer setting, these techniques have almost
been abandoned due to the concern for radiation
exposure, especially during repeated examinations.
In addition, modern multiple gated acquisition
scans may not allow optimal patient positioning for
LVEF assessments (6). The limits of agreement
between multiple gated acquisition scans and CMR
for LVEF are wide (19.4% to 16.5%). At an LVEF
threshold of 50% to define cardiotoxicity, there is
a risk of misclassifying 35% of cancer patients (21).
It is also important to note the additional
limitation of ERNA due to its inability to evaluate
right ventricular, valvular function, or pericardial
disease.
Although CCT has the capability of providing a
measurement of LV volumes and LVEF, it comes at the
cost of radiation exposure. Therefore, CCT does not
have a routine role in the surveillance of cardiac
function during cardiotoxic cancer therapy.
Surveillance and detection of CTRCD is currently
performed by using echocardiography-derived LVEF
and, more recently, strain imaging (6). The overall
goals are: 1) correct adjudication of stage B heart
failure, so that modern heart failure therapy can
be initiated; 2) accurate calculation of LV volumes in
the assessment of LV remodeling; and 3) potential
identification of situations where changes in loadingconditions may be playing a role in changes in LVEF
or strain.
The best method for measuring LVEF to identify
early cardiovascular injury is still unclear.
CMR can identify small changes in LVEF that
appear to parallel the changes in myocardial strain
(22). However, whether such small early changes
predict subsequent CTRCD or are just the result of
hemodynamic variability is unclear (23). CMR may be
useful clinically in situations where there is concern
regarding echocardiographic or ERNA calculation of
LVEF or in situations where a more accurate and
precise LVEF measurement is needed to inform de-
cisions regarding chemotherapy discontinuation (6).
Interestingly recent work in female patients
receiving therapy for breast cancer has suggested that
nadir LVEF values are identified by 3D echocardiog-
raphy earlier than 2D echocardiography, suggesting
that 3D measured LVEF may be a useful method to
identify early cardiac injury (24). For adjudication of
stage B heart failure during cancer therapy, based on
a single study, 3D LVEF appears to identify more
CENTRAL ILLUSTRATION Cardiovascular Complications of Cancer Therapy
Plana, J.C. et al. J Am Coll Cardiol Img. 2018;11(8):1173–86.
Stages of the evaluation and clinical conditions to be evaluated and imaging modalities available. CAD ¼ coronary artery disease; CMR¼ cardiovascular magnetic
resonance; CT ¼ computed tomography; PET ¼ positron emission tomography.
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does (25). Accurate calculation of LVEF should be
done with the best method available in the echocar-
diography laboratory (ideally, 3D echocardiography)
(6). It is important to recognize that, although ideal,
the technique or the expertise in interpretation may
not be widely available outside academic centers. In
such scenarios, ultrasound-enhancing agents should
be used to enhance 2D echocardiography when 2contiguous LV segments are not well visualized on
noncontrast apical images (6). The LV volumes ob-
tained will be larger with closer correlation with CMR.
The recently published clinical applications of ultra-
sonic enhancing agents in echocardiography reported
a study examining baseline pre-chemotherapy echo-
cardiograms in female patients, where 51% of
contrast-enhanced diastolic volumes were classified
as abnormal, despite the LV dimensions being within
TABLE 2 Temporal Changes in Cardiac Function, Biomarkers, and Symptoms in the
Clinical Case Presented
Intervals of Follow-Up 3D EF 2D EF GLS HsTpI, ng/ml
NYHA Functional
Class
Pre-cancer therapy 61 64 21.5 2 I
Post-anthracycline therapy 53 55 17.9 48 I
1 month into trastuzumab
(Herceptin) therapy
48 47 15.1 102 II–III
6 weeks 56 60 19.2 17 I
6 months 53 54 17.8 8 I
9 months 53 58 18.1 3 I
12 months 53 55 17.1 2 I
24 months 52 54 17.9 – I
EF ¼ ejection fraction; HsTpI ¼ highly sensitive troponin I; NYHA ¼ New York Heart Association; other
abbreviations as in Table 1.
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1177the normal range by unenhanced 2D volume mea-
surements. To account for this change in normal
range, the document proposed an end diastolic vol-
ume upper limit cutoff of 83 ml/m2 for women and
98 ml/m2 for males (26). Armstrong et al. (27)
compared LV volumes measured using 2D and 3D
echocardiography to volumes measured using CMR.
They found that, although the 3D calculated left
ventricular end-diastolic volume (LVEDV) and left
ventricular end-systolic volume (LVESV) were closer
to those calculated by using CMR, there was still
underestimation (mean EDV: 12.4 ml/m2; mean ESV:
5.3 ml/m2; p < 0.001 for both).
LV volumes and EF are not fixed for a given in-
dividual. They fluctuate, reflecting dynamic changes
in loading conditions and inotropic state. A reduc-
tion in LVEF can be due to either an increase in
LVESV or reduction in LVEDV. In patients treated
with anthracycline and/or trastuzumab, the primary
driver for a reduction in LVEF is an increase in
LVESV (22,28–30) Patients may exhibit potential re-
ductions in LVEDV caused by intravascular volume
depletion (reduced preload) from cancer therapy-
related poor oral intake, vomiting, or diarrhea. Two
recent studies of various cancers in patients
receiving chemotherapy demonstrated that 16% to
19% of patients who met criteria for CTRCD showed
only an isolated reduction in LVEDV without a
“significant” increase in LVESV (23,31). This has
important implications for clinical management of
subclinical LV dysfunction and CTRCD and is a cause
for further investigation. However, several concepts
should be considered when interpreting these data.
First, up to 6% variability in LVEF and 21 ml in
LVEDV can occur with CMR measurements due to
variability in contouring the basal short axis slice.
However, newer software analysis tools allow
tracking the motion of the mitral and aortic valves’
planes through the cardiac cycle, minimizing the
variability in LV volumes calculations. This is
particularly important in longitudinal studies where
even the acquisition of the basal slice could be
different due to variability in image setup (32,33).
Second, based on cardiac physiology, a reduction in
LVEDV does not occur in isolation. It is associated
with a sympathetic reflex that increases inotropy,
which in turn will increase the slope of the end-
systolic pressure–volume relationship. In addition,
the reduction in stroke volume results in reduced
systemic pressure with subsequent reduction in
afterload. In combination, the LVESV also decreases.
This concept is supported by recent work in which
healthy individuals subjected to 2.0% to 3.5% intra-
vascular volume depletion had a reduction in bothLVEDV and LVESV without a statistically significant
reduction in LVEF or circumferential strain (34).
Therefore, the lack of a reduction in LVESV associ-
ated with a reduction in LVEDV seen in these recent
studies suggests a concomitant reduction in
myocardial contractility to explain the reduction in
LVEF. Finally it is important to recognize without
making CMR the technique to routinely follow pa-
tients during cancer therapy that our echocardiog-
raphy techniques do not have the ability to identify
small changes in ventricular volumes during cancer
therapy (8). Hence, using ventricular volumes as
surrogates for intravascular status would not be
practical in routine clinical practice.
The findings of potential volume dependency of
LVEF measurements further emphasize the impor-
tance of repeating cardiac imaging 2 to 3 weeks later
upon discovery of subclinical LV dysfunction or
CTRCD, before consideration of changes to cancer
therapy or initiation of cardiac medications (6). It also
is important to perform surveillance imaging at times
when patients’ intravascular volumes are less likely
to be depleted, such as the day before the next
chemotherapy cycle.
Evaluation of LV deformation: strain imaging. Negishi
et al. (35) found that the strongest predictor of CTRCD
was delta 2D-based GLS during treatment. An 11%
reduction (95% confidence interval [CI]: 8.3% to
14.6%) half way through trastuzumab therapy was the
optimal cutoff, with a sensitivity of 65% and a spec-
ificity of 94% for subsequent cardiotoxicity. GLS was
an independent early predictor of later reductions in
LVEF, incremental to usual predictors in patients at
risk for trastuzumab-induced cardiotoxicity. Their
findings served as the scaffolding for the subse-
quently published expert consensus that recom-
mends the use of GLS for the surveillance of
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MRI as Tool to Understand the Underlying Mechanisms of Cardiotoxicity
(global LV dysfunction, interstitial fibrosis, replacement fibrosis, myocardial edema)
CMR studies in a patient during (A) and after 6-month withdrawal of trastuzumab (B): end-diastolic (EDV) frame, end-systolic (ESV) frame, feature tracking analysis and
curves for GLS and radial strain and native T1 mapping. At 6-month withdrawal, both EDV and ESV are reduced, ejection fraction increased, global longitudinal and
radial strain improved, and native T1 values were reduced. This case demonstrated the reversible nature of trastuzumab cardiomyopathy. (C) CMR study in a patient with
anthracycline-cardiomyopathy, with reduced EDV and ESV, reduced ejection, impaired global longitudinal strain, and presence of subepicardial and mid-wall late
gadolinium enhancement (LGE) in the septum, inferior, and inferolateral walls. CMR ¼ cardiac magnetic resonance; EDV ¼ end-diastolic volume; ESV ¼ end-systolic
volume; LGE ¼ late gadolinium enhancement; LVEF ¼ left ventricular ejection fraction.
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1178subclinical LV dysfunction for patients being treated
with anthracyclines or trastuzumab with a reduction
of >15% compared to baseline illustrating a clinically
significant change (6). Nevertheless, the association
between GLS and subsequent CTRCD might have
been potentially misinterpreted, postulating first,
that GLS falls before LVEF in patients receiving car-
diotoxic therapies and, second, that there is a
compensatory increase in GCS in response to the
reduction in GLS in order to initially preserve LVEF.
Recent work (36) can help us understand the rela-
tionship between LVEF and its determinants: GCS,
GLS, LV internal dimension, and wall thickness. The
model showed that GCS contributes more than twice
as much to LVEF than GLS. For the LVEF to be
maintained, a reduction of GLS needs to be compen-
sated by an increase in GCS or wall thickness or
reduced LV diameter. In the above- mentioned study
by Negishi et al. (35), LVEF, GLS, and GCS decreasedin parallel from baseline to 12 months, from 58  5.5%
to 55  5.3%; from 20.7% to 18.3%; and
from 17.8% to 15.9%, respectively. Global radial
strain decreased from 50.9% to 45.7%. Other studies
have also demonstrated simultaneous reductions in
all these parameters (11,37).
Six-month data from the study by Negishi et al.
(35) can help us understand the limitations of
using 2D echocardiography and the role of 2D-based
strain for the early detection of subclinical LV
dysfunction. LVEF decreased from 64  4.6% to
58  5.5% (a 6 absolute point reduction in LVEF),
which is below the 10-point threshold ability of 2D-
based echocardiography to discriminate sequential
changes in LVEF (8). At the 12-month follow-up, LVEF
continued to deteriorate, reportedly at 55  5.3%
(9 absolute point reduction in LVEF), very close
to the threshold, giving the reader the ability to
recognize the change. In parallel, there was a
FIGURE 2 Myocarditis Identified by CMR
A B
(A) Focal area of myocardial edema is shown in a T2-weighted sequence (SPAIR) image (arrow). (B) Subepicardial enhancement (arrow) on
late gadolinium-enhanced images, reflective of myocardial cell death. Subepicardial enhancement is a pattern often seen in myocarditis.
SPAIR ¼ spectral attenuated inversion recovery; other abbreviation as in Figure 1.
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1179reduction in GLS from 20.7  2.6% to 18.3  2.1% at
6 months (2.4 absolute point reduction, 11.6% relative
reduction compared to baseline), which remained
unchanged at 12 months. The lower intra- and inter-
observer variability values of GLS allow easier
recognition of the change in systolic function than
LVEF. The relative mean error for GLS was 1.7 (below
the 2.4 change noted during surveillance), making
2D-based strain well suited for the identification of
subclinical LV dysfunction (38).
Using CMR, Drafts et al. (22) initially reported on
the behavior of LVEF and GCS at 1, 3, and 6 months in
53 patients receiving low-dose anthracyclines (50 to
375 mg/m2) for the treatment of breast cancer, leu-
kemia, and lymphoma. LVEF and GCS decreased
from baseline to 6 months 58  1% to 53  1%
(p ¼ 0.0002) and from 17.7  0.4% to 15.1  0.4%
(p ¼ 0.0003), respectively (22).
In 101 patients receiving cardiotoxic agents in the
setting of various malignancies, Jordan et al. (31)
subsequently published data incorporating CMR mid-
wall Eulerian GCS, including this time GLS (n ¼ 34,
using high-temporal resolution 2- and 4-chamber cine
views), and LVEF. Overall, GLS declined from 15.44
to 14.79 (p ¼ 0.069), GCS from 17.99% to 17.23%
(p ¼ 0.0052), and LVEF from 59.2% to 56.7%
(p ¼ 0.0002), respectively.
LV mass was unchanged by CMR in the patients
who developed CTRCD. The diameter of the ventricle
increased only slightly during and after anthracycline
therapy (22).Data from these echocardiographic and CMR
studies suggest that the reduction in LVEF may be
explained by the parallel reduction in GLS and GCS,
with slight contribution from the increase in LV in-
ternal dimension. The apparent misconception that
GLS changes before LVEF appears to be explained by
the inability of 2D-based echocardiography to recog-
nize changes <10%. Larger studies ideally using CMR-
based LVEF and strain are needed to study this
concept further.
The significant interest in triplane and 3D speckle
tracking is currently limited by the poor correlation of
values of this technique compared with 2D-based
strain. There are 2 explanations: the limited feasi-
bility due to poor tracking of the segments and the
differences in acquisition rates (low volumes per
second compared to the high frame rates attainable
with its 2D counterpart). We are hopeful that tech-
nology will evolve over time and overcome these
challenges (39).
Tissue characterization. CMR may facilitate our under-
standing of the pathogenesis of CTRCD. Myocardial
tissue changes such as intracellular and interstitial
edema and fibrosis may precede the alterations in
LV volumes, reduction in LVEF, or changes in
myocardial strain and may represent early markers of
myocardial injury. Multiple CMR imaging sequences
such as T1- and T2-weighted imaging, as well
as newer T2 and T1 mapping sequences, can help
identify intracellular and interstitial edema and are
now part of our armamentarium (Figure 1) (40,41).
FIGURE 3 Cardiac Computed Tomography for Assessment of CAD
A B C
(A) Pericardial calcification in patients who had previously undergone chest radiation. (B) Significant proximal coronary artery disease
involving the LAD artery. (C) Mixed plaque in the proximal LAD in a patient experiencing chest pain during treatment with 5-fluorauracil.
LAD ¼ left anterior descending artery; other abbreviations as in Figure 1.
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1180Native T1 mapping or a combination of pre- and
post-contrast T1 mapping can be used to calculate
extracellular volume fraction (ECV) as a marker
of edema or interstitial fibrosis (42). Post-contrast
T1-weighted imaging (late gadolinium enhancement
[LGE]) can be used to identify myocardial replace-
ment fibrosis.
Several small studies using CMR have shown
myocardial edema early following anthracycline
therapy, by using T2-weighted sequences (30,43).
The presence of edema has been associated with
persistent reduction in RV function in follow-up
examinations (30). CMR studies have also demon-
strated presence of focal and replacement fibrosis
with variable patterns (epicardial, mid-wall, inser-
tion points) and incidence. Nevertheless, this finding
has not been consistent in published reports (41).
Also, there is accumulating evidence of the presence
of diffuse interstitial fibrosis measured by native T1
mapping and ECV in anthracycline-induced cardio-
myopathy. It manifests independently of the pres-
ence of cardiovascular comorbidities and is
associated with impaired diastolic function (44,45).
In cancer survivors, an increase in ECV has been
associated with higher anthracycline doses and
lower exercise capacity (46). In this latter cohort, the
increase in ECV is likely a marker of interstitial
fibrosis.
Some CMR studies have described subepicardial
LGE of the lateral wall in patients with trastuzumabcardiomyopathy, suggesting an underlying myocar-
ditis, however, this has not been reproduced in other
studies (47,48). Although the presence of LGE has
been associated with prognosis in a range of ischemic
and nonischemic cardiomyopathies, there are no
similar data in patients with CTRCD (49). However,
LGE imaging may have value in evaluating patients
receiving cancer immunotherapy with a clinical sus-
picion of myocarditis. Cardiotoxicity related to
immunotherapy includes heart failure, Takotsubo-
like syndrome, and fulminant myocarditis with fatal
outcome (50). CMR is known to be a valuable mo-
dality for detection of myocarditis, using the Lake
Louise criteria (51). Although this has not been
formally evaluated in the setting of immune therapy,
a recent case series of 35 patients with immune
therapy-mediated myocarditis identified LGE in a
mid-myocardial, subepicardial, or diffuse pattern in
77% of the patients (Figure 2) (52).
Myocardial metabolism. PET imaging provides a
unique assessment of myocardial metabolism,
which may identify the earliest myocardial or
vascular changes related to toxicity. Although
changes in fluorodeoxyglucose uptake appear to
identify patients at risk of doxorubicin-mediated
cardiotoxicity (53), the use of PET imaging to
identify early cardiotoxicity is still limited to the
research realm.
Complementary role of biomarkers. Several biomarkers
have been proposed for early detection of CTRCD.
FIGURE 4 Assessment of Pericardial Constriction Using CMR
A B C
(A) T1-weighted spin echo sequence demonstrates thickening of the pericardium (arrow). (B, C) Real-time cine sequence showing normal
position of the interventricular septum at expiration, but shifted (B) into the LV during inspiration (C). This respirophasic septal shift is a
hemodynamic feature of constrictive physiology. LV ¼ left ventricle; other abbreviations as in Figure 1.
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1181The biomarkers most studied are troponin (Tn),
resulting from cardiomyocyte damage and natriuretic
peptides, reflecting elevation in left ventricular filling
pressure and wall stress. Tn is recognized as a highly
efficient predictor of early and long-term cardiac
toxicity. Cardinale et al. (54–56) had previously
demonstrated that Tn subunit I (TnI) positivity soon
after initiating regimens containing anthracyclines is
a strong predictor of LVEF reduction and poor cardiac
outcome, particularly in patients showing persistent
(>1 month) Tn positivity. Cardinale et al. (57) also
showed that, in trastuzumab-treated patients, TnI
evaluation provided an opportunity to recognize pa-
tients at risk of developing trastuzumab-induced
CTRCD, and among them, those who were less likely
to recover from it despite optimal therapy for heart
failure. There is debate regarding the clinical useful-
ness of the measurement of natriuretic peptides
because of discordant results (1,2). Notably, data for
the complementary role of biomarkers to imaging in
cancer patients are limited but encouraging. Sawaya
et al. (58) showed a negative predictive value of 91%
when a decrease in GLS (<19%) was combined with an
elevation of ultrasensitive TnI in breast cancer
patients receiving doxorubicin and trastuzumab.
Similarly, the combination of elevated TnI and mye-
loperoxidase levels was shown to identify a group of
patients with breast cancer at increased risk for car-
diotoxicity better than each individual biomarker
alone (59). A combined multimodality imaging
and biomarker approach in selected individuals may
thus be of interest for risk prediction and to guide
therapy.DETECTION OF PULMONARY HYPERTENSION.
Pulmonary hypertension can occur during cancer
treatment due to venous thromboembolism, com-
pression by the tumor, or due to use of tyrosine ki-
nase inhibitors such as dasatinib. Echocardiography
remains the primary method to screen for pulmonary
hypertension during treatment through the mea-
surement of right ventricular systolic pressure from
the tricuspid regurgitation jet.
VASCULAR TOXICITY. There has been growing in-
terest in expanding our understanding of the effects
of cancer therapeutics in the cardiovascular system
beyond the heart. Arterial stiffness by pulse wave
velocity (PWV) can identify vascular changes in the
asymptomatic subclinical stage: vascular ultrasonog-
raphy can be used to assess both the local and
carotid–femoral arterial stiffness, whereas CMR can
be used to assess both local and central arterial
stiffness. Di Lisi et al. (60) recently reviewed cancer
therapy-induced vascular toxicity. Useful imaging
biomarkers in this context are the noninvasive
flow-mediated dilation (flow hyperemia-mediated
dilation) of the brachial artery to detect endothelial
dysfunction and increased intima–media thickness of
the common carotid artery measured by ultrasonog-
raphy. Using CMR, the thoracic aortic PWV, a marker
of vascular stiffness, appears to increase steadily after
the administration of anthracyclines. Although
adjusting for baseline heart rate had minimal impact
on the change in velocity over time, participants with
a higher systolic blood pressure had a higher PWV at
rest and a faster increase in PWV, highlighting
the interaction between the effects of the
FIGURE 5 Stress CMR for the Assessment of Inducible Myocardial Ischemia and Viability
A
B
(A) Significant peri-infarct ischemia (white arrow) in the basal to mid-cavity of the anterior wall (LAD territory) in a 57-year-old male with a
history of chemotherapy and radiation for small-cell lung cancer. Basal, mid-, and apical short-axis slices are from stress first-pass perfusion
images using a gradient echo (GRE) sequence after adenosine infusion and administration of 0.1 mmol/kg gadolinium chelate contrast agent.
(B) Corresponding basal, mid-, and apical short-axis slices from late gadolinium- enhanced images using an inversion recovery (IR)-GRE
sequence 15 to 20 min after contrast administration. There is a focal subendocardial infarction in the mid-cavity anterior wall (arrow).
Abbreviations as in Figure 4.
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1182chemotherapeutic agents and the baseline risk fac-
tors of the patient. Aortic distensibility also can be
assessed by gated CT, but both the radiation
burden and the lower temporal resolution (which
may lead to underestimation of distensibility) limit
its use in this context (61). Despite these interesting
findings, whether these early changes result in
subsequent symptomatic vascular disease remains
unknown.
PREDICTION OF RECOVERY OF
CARDIOVASCULAR TOXICITY
CTRCD. Once there is a reduction in myocardial
function identified during cancer therapy, there are
very few data for predictors of recovery other thanthe timing of heart failure therapy initiation (62).
In patients receiving sequential anthracycline and
trastuzumab-based therapy, nadir GLS value greater
than 15.8% may identify patients at higher risk of
lack of LVEF recovery (hazard ratio [HR]: 0.39; 95%
CI: 0.18 to 0.74) (63). Similarly, in anthracycline-
treated patients, lower LVEF at initiation of HF
treatment may be associated with lack of recovery of
ventricular function (64). The only other imaging
predictors of ventricular function recovery is larger
left atrial volume (odds ratio [OR]: 0.94; 95% CI: 0.88
to 0.99) (65). These parameters together suggest that
those who have more severe myocardial dysfunction,
as measured by EF, strain, or atrial remodeling at
initiation of HF therapy, are less likely to have
recovery of heart function.
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1183DETECTION OF CARDIOVASCULAR DISEASE
IN LONG-TERM CANCER SURVIVORS
DETECTION OF CTRCD. The high risk for adult
onset CTRCD after treatment for childhood and
adolescent neoplasia warrants early detection when
intervention is expected to be of greater benefit.
Children’s Oncology Group long-term follow-up
guidelines recommend periodic evaluation by
echocardiography. Conventionally, the measure-
ment has been obtained using 2D echocardiography.
In cancer survivors, compared with CMR, the
sensitivity and false negative rate improved from
25% and 75% to 53% and 47%, respectively, when
using 3D echocardiography instead of 2D echocar-
diography, reducing the misclassification rate of
stage B heart failure patients as normal from 11% to
5% (27). However, in a larger cohort of 1,820 adult
survivors of childhood cancer, although only 5.8%
of the patients had abnormal 3D LVEF (<50%),
32.1% of survivors with normal 3D LVEF had cardiac
dysfunction by GLS (28%) or by diastolic assessment
(8.7%) or both. Abnormal GLS was associated with
the dose of chest radiation and anthracycline-based
chemotherapy received. Interestingly, survivors
with the metabolic syndrome were twice as likely to
have abnormal GLS or diastolic dysfunction. The
authors concluded that the use of modern echo-
cardiography may allow identification of a subset of
survivors who may benefit from early medical
intervention (66).
CMR-based ECV has been examined as a measure
of subclinical cardiac injury in both pediatric and
adult cancer survivors. In pediatric cancer survi-
vors, ECV appears to be associated with total
anthracycline dose, markers of adverse ventricular
remodeling, and lower maximum VO2 (46). In adults
treated with anthracyclines, ECV fraction is
increased in cancer survivors compared to that in
controls, with higher values in those with reduced
versus those with preserved LVEF (45). Elevated
ECV is also correlated with measures of worse dia-
stolic dysfunction such as higher lateral annular E0
velocity and E/e0 ratio. Compared to matched con-
trols and a separate cohort of patients who under-
went imaging prior to cancer therapy, ECV values
appeared to be elevated, particularly in those
receiving anthracycline-based therapy (44). These
data suggest that increased ECV may occur in can-
cer survivors with preserved or reduced LVEF and
that it identifies a cohort of patients with poten-
tially vulnerable myocardium. Whether these
abnormalities have future implications for thecardiovascular health of patients remains to be
determined.
In addition to LV dysfunction, recent studies of
lymphoma survivors have also described right ven-
tricular (RV) systolic dysfunction. The association
between LV function (LV GLS) and RV function
(tricuspid annular plane systolic excursion), indi-
cated a global long-term cardiotoxic effect. However,
RV dysfunction (6.2%) was less prevalent than LV
dysfunction (30.8%) (p < 0.001) (67,68).
DETECTION OF PERICARDIAL DISEASE. Pericardial
disease can be seen as a long-term consequence of
radiation therapy to the chest. Echocardiography
remains the primary modality for screening for
pericardial constriction in patients with suggestive
symptoms (69). Cardiac CT can help assess the
presence and extent of pericardial calcification
(Figure 3). In patients in whom echocardiography is
not diagnostic, CMR also provides an assessment of
the presence of pericardial thickening, pericardial
effusion, its extent, and an assessment of the
constrictive physiology (Figure 4) (69).
DETECTION OF VASCULAR TOXICITY. Radiation-
induced cardiovascular disease appears to be associ-
ated with damage to endothelial cells through
transient increases in oxidative stress, impaired
vascular wall homeostasis, endothelial dysfunc-
tion and apoptosis of endothelial cells with sub-
sequent inflammatory response leading to increased
expression of matrix metalloproteinases, adhesion
molecules, and proinflammatory cytokines and,
downregulation of vasculoprotective nitric oxide,
leading to accelerated atherosclerosis, increased
blood viscosity and unstable platelet aggregates (70).
Arterial stiffness is a precursor of atherosclerosis and
is increased in irradiated arteries, in keeping with
radiation-induced damage. Early and late changes in
markers of aortic stiffness with breast cancer therapy
was measured using CMR at baseline and at, 4, and 14
months post-therapy measuring aortic PWV and
distensibility at ascending aorta and proximal
descending aorta. The study demonstrated that acute
changes are observed in PWV and distensibility at the
ascending aorta following contemporary breast cancer
chemotherapy and partially reverse a year after ther-
apy is discontinued, with more severe effects seen
with anthracyclines (71). Childhood cancer survivors
show reduced vascular health (72), and increased
arterial stiffness following chemotherapy (73). The
long-term effects of radiation therapy on arterial
stiffness may have a role on increasing cardiovascular
risk in women treated for breast cancer (74).
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1184The assessment of coronary calcium and obstruc-
tive CAD can be achieved robustly by using CCT
(Figure 3) and stress CMR (Figure 5). In survivors,
a coronary calcium score may help with risk stratifi-
cation and may guide intensity of risk factor
modification.
DISCUSSION OF THE PATIENT’S CASE
Our patient had no conventional cardiovascular risk
factors. Although her baseline 3D LVEF and GLS were
normal, her GCS was mildly reduced, which may be a
pre-treatment risk of CTRCD (Table 2).(11) She had a
reduction in 3D LVEF immediately post anthracycline
but it did not meet CTRCD criteria. However, she had
>15% relative reduction in GLS, meeting criteria for
subclinical LV dysfunction (6). Given the absence of
convincing data for intervention with isolated
reduction in GLS, no cardiac therapy was instituted.
She presented 1 month later with stage C heart fail-
ure. Her lowest GLS was measured at 15.1%, sug-
gesting that there is a reduced chance of completed
LVEF recovery (63). With 2 trastuzumab cycles held
and initiation of beta-blockers and angiotensin-
converting enzyme inhibitors (ACEi), her LVEF and
GLS improved; however, despite w2 years of cardiac
medications, her GLS and LVEF remains mildly
reduced.
OUTCOMES IN CARDIO-ONCOLOGY AND
FUTURE DIRECTIONS
The goal for the cancer patient is to fully administer
the prescribed regimen with no interruptions, aiming
at cure or remission, with a survival free of cardio-
vascular morbidity and mortality. This brings us tothe question of the optimal outcome to follow in
cardio-oncology?
We propose to strengthen the partnership between
imaging, oncology and heart failure specialists and,
very importantly, the cancer patient, so as a group we
can come to an agreement as to the outcomes we
believe will matter, so we can use them effectively to
understand and mitigate the cardiovascular toxicity
of old and new agents. We anticipate that the oncol-
ogists will include the ability to deliver full and un-
interrupted regimens. The imagers would like to
include LV volumes, LVEF, and mass and deforma-
tion indices. Our heart failure colleagues will obvi-
ously be interested in the accurate adjudication of
cardiomyopathy, heart failure, and cardiovascular
mortality, as well as the use of biomarkers (Tn, BNP,
and N-terminal pro–B-type natriuretic peptide) and
tests evaluating functional exercise capacity (6-min
walk test and maximum VO2). The patient would
likely add quality of life to the above-mentioned
metrics.
Regardless of our field of expertise, we have one
shared goal: cancer survival without cardiovascular
disease. We look forward to continuing the advance-
ment of the field of multimodality imaging with the
hope of achieving this goal through the demonstra-
tion of impact on outcomes.
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